Vaccine Market is Projected to Reach a Value of US$ 48.0 Bn by 2025

1
(Human Vaccines Hepatitis, Influenza,
Meningococcal, Pneumococcal, HPV, Combination
Vaccines Animal Vaccines Canine, Feline,
Porcine, Bovine, Ovine, Poultry and
EquineForecast 2014 - 2020
Vaccine Market
2
Table of Content
Sr. No. Content
Chapter1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary
Chapter 4 Market Overview
Chapter 5 Market Analysis, by Component
Chapter 6 Market Analysis, by Data Type
Chapter 7 Market Analysis, by Application
Chapter 8 Market Analysis, by Region
Chapter 9 Competition Landscape
Chapter 10 Company Profiles
Chapter 11 Key Takeaways
3
Vaccine Market Snapshot

• A vaccine is a biological preparation of killed
  forms of microbes, living attenuated organisms,
  living fully virulent organisms, a microbes
  toxins or one of its surface proteins.
• The U.S. human vaccine market can be classified
  into pediatric and adult vaccines, in terms of
  the type of vaccines. 
• Rising Cases of Vector Borne Diseases to Propel
  Market
• Increasingly strict guidelines and regulations
  for the lengthy and time consuming approval
  process has resulted in the increase in cost of
  several new vaccines. 

4
Reports Highlights

• U.S. vaccine market was valued at USD 12.8
  billion in 2013 and is expected to grow at a CAGR
  of 4.3 from 2014 to 2020, to reach an estimated
  value of USD 17.3 billion in 2020.
• Key Players
• GlaxoSmithKline plc, Merck Co., Inc., Novartis
  International AG, Pfizer, Ltd., Sanofi,
  Boehringer Ingelheim and Zoetis, Inc.

Request Sample
5
(No Transcript)